Rebaudioside A loaded poly-d,l-lactide-nanoparticles as an anti-diabetic nanomedicine

Rebaudioside A is a major constituent (20% w/w) of natural stevioside powder and possess strong insulinotropic (anti-diabetic) activity with an extra glucose molecule than stevioside. In this manuscript, we have reported the nanofabrication of pure rebaudioside A and its effect on size, encapsulation efficiency and in vitro release. These results have been compared with stevioside nanoparticles using same synthesis process to evaluate the effect of extra glycosylation on nanoencapsulation (Colloids and surfaces B: Biointerfaces, 101 (2013) 510-516). Mono-disperse rebaudioside A-PLA nanoparticles of larger size (150-200 nm) than stevioside NPs (110-130 nm) were obtained along with 28.57% molecular loading efficiency (w/w%). However, rebaudioside A-PLA nanoparticle shows similar in vitro burst and sustained release upto 200 h as nano-stevioside. This study reveals that rebaudioside A-PLA nanoparticles can be used as a better antidiabetic nanomedicine than previously reported stevioside PLA nanoparticles.